<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04941768</url>
  </required_header>
  <id_info>
    <org_study_id>MS100070_0110</org_study_id>
    <nct_id>NCT04941768</nct_id>
  </id_info>
  <brief_title>An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION)</brief_title>
  <official_title>Real-world Evaluation of Efficacy and Safety With Avelumab (BAVENCIO®) + Axitinib (INLYTA®) in Patients With aRCC in Multiple EU Countries (AVION)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Serono GmbH, an affiliate of Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</source>
  <brief_summary>
    <textblock>
      The main purpose of this study is to expand knowledge on the effectiveness of Avelumab&#xD;
      intravenous infusion in combination with Axitinib as the first-line therapy in participants&#xD;
      with advanced renal-cell carcinoma (aRCC) in addition to the safety and tolerability under&#xD;
      routine conditions of daily clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 9, 2021</start_date>
  <completion_date type="Anticipated">June 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS) Rate at Month 12</measure>
    <time_frame>Time from first dose of study drug up to Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Rate at Month 24</measure>
    <time_frame>Time from first dose of study drug up to Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Time from first dose of study drug to the date of death from any cause, assessed up to Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response (OR) Rate Assessed by Investigator at Month 24</measure>
    <time_frame>Time from first dose of study drug up to Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) Assessed by Investigator at Month 24</measure>
    <time_frame>Time from first dose of study drug up to Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1</measure>
    <time_frame>Time from first dose of study drug up to Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 Assessed by Investigator</measure>
    <time_frame>Time from first dose of study drug to the date of disease progression or death from any cause, assessed up to Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival 2 (PFS2) According to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 Assessed by Investigator</measure>
    <time_frame>Time from first dose of study drug to the date of disease progression on second-line treatment or death from any cause, assessed up to Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality Of Life (HRQoL) According to National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index 19 (NCCNFACTFKSI-19)</measure>
    <time_frame>Baseline, Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs), Related AEs, AEs Leading to Permanent Treatment Discontinuation and AEs Leading to Death According to Medical Dictionary for Regulatory Activities (MedDRA)</measure>
    <time_frame>Time from first dose of study drug up to Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) Based on Severity According to National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0</measure>
    <time_frame>Time from first dose of study drug up to Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Greater Than of Equal to (&gt;=) Grade-3 Adverse Events (AEs) Leading to Discontinuation According to Medical Dictionary for Regulatory Activities (MedDRA)</measure>
    <time_frame>Time from first dose of study drug up to Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Avelumab plus Axitinib Therapy Among Participants Who Discontinued the Study Drugs Due to All-Cause Adverse Events (AEs) Greater Than or Equal to (&gt;=) Grade 3</measure>
    <time_frame>Time from first dose of study drug up to Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of All-cause Adverse Events (AEs)</measure>
    <time_frame>Time from first dose of study drug up to Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of All-cause Adverse Events (AEs)</measure>
    <time_frame>Time from first dose of study drug up to Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with All-cause Adverse Events (AEs) Outcomes (Resolved, Resolving, not Resolved, Resolved with Sequelae, Fatal, Unknown)</measure>
    <time_frame>Time from first dose of study drug up to Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Therapy Modifications Due to Adverse Event Related to Avelumab plus Axitinib Therapy</measure>
    <time_frame>Time from first dose of study drug up to Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Different Types of Medical Intervention or Medications Used for the Management of Adverse Events (AEs) Related to Avelumab plus Axitinib Therapy</measure>
    <time_frame>Time from first dose of study drug up to Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Receiving Later-line therapy</measure>
    <time_frame>Time from first dose of study drug up to Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Second-line Therapy Initiation</measure>
    <time_frame>Time from Avelumab plus Axitinib therapy discontinuation to the initiation of second-line therapy, up to Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Patient-reported Potential Signs and Symptoms of Immune-related Adverse Events (AEs)</measure>
    <time_frame>Time from first dose of study drug up to Month 24</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Carcinoma, Renal Cell</condition>
  <arm_group>
    <arm_group_label>Avelumab + Axitinib</arm_group_label>
    <description>There will not be any study-specific interventions in this study. Participants with advanced RCC receiving 800 milligrams (mg) of Avelumab intravenously every 2 weeks in combination with 5 mg of Axitinib orally twice per day in accordance with the terms of marketing authorization for the first-line therapy as per the current clinical practice will be observed for 24 months in this study.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with a confirmed diagnosis of advanced RCC will be observed in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants with the Eastern Cooperative Oncology Group (ECOG) performance status 0,&#xD;
             1, or 2&#xD;
&#xD;
          -  Participants with a histologically confirmed diagnosis of RCC with any histological&#xD;
             origin&#xD;
&#xD;
          -  Participants with a locally advanced/metastatic disease (that is [ie], newly diagnosed&#xD;
             Stage 4 RCC per American Joint Committee on Cancer) or has recurrent disease&#xD;
&#xD;
          -  Participants has received 1 or 2 cycles of Avelumab plus Axitinib treatment as a&#xD;
             first-line therapy according to the approved Summary of Product Characteristics (SmPC)&#xD;
&#xD;
          -  Participants willing to sign the written informed consent form (ICF) to participate in&#xD;
             this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with contraindications for Avelumab or Axitinib according to the approved&#xD;
             SmPC&#xD;
&#xD;
          -  Participants who have participated in any interventional clinical study of a drug or&#xD;
             device within 28 days prior to the start of Avelumab plus Axitinib&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@emdgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Imelda Ziekenhuis</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ KLINA</name>
      <address>
        <city>Brasschaat</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Z.O.L. Campus Sint Jan</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum St. Marien Amberg</name>
      <address>
        <city>Amberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Aschaffenburg Medizinische Klinik</name>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>GFO Kliniken Rhein Berg</name>
      <address>
        <city>Bergisch Gladbach</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Bielefeld</name>
      <address>
        <city>Bielefeld</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis Dr. U. Kube</name>
      <address>
        <city>Chemnitz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Donauisar Klinikum Deggendorf</name>
      <address>
        <city>Deggendorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Dessau</name>
      <address>
        <city>Dessau-Rosslau</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urologische Gemeinschaftspraxis</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniklinik Duesseldorf Poliklinik fuer Urologie</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Georg Klinikum Eisenach gGmbH</name>
      <address>
        <city>Eisenach</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen Uroonkologie</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologische GP Dres. Wilke/Wagner/Petzoldt</name>
      <address>
        <city>Fürth</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologische SP Praxis Fürth</name>
      <address>
        <city>Fürth</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MVZ Onkologische Kooperation Harz GbR</name>
      <address>
        <city>Goslar</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Maas</name>
      <address>
        <city>Halberstadt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vinzenzkrankenhaus Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Kretz</name>
      <address>
        <city>Heinsberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätskinderklinik Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Städt. Klinikum Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniklinik Koeln, Klinikum für Urologie</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis Dr. Ralf Eckert</name>
      <address>
        <city>L.-Eisleben</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bonifatius Hospital Lingen</name>
      <address>
        <city>Lingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis Dipl. Med. Susanne Kloss</name>
      <address>
        <city>Luckenwalde</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>axel.merseburger@uksh.de</email>
    </contact>
    <investigator>
      <last_name>Axel Merseburger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Akademie Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis für Hämatologie und Onkologie</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden der Mühlenkreiskliniken (AöR)</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München A.ö.R.</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Munster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lukaskrankenhaus GmbH</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Paracelsus Klinik Osnabrück</name>
      <address>
        <city>Osnabrück</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>GPR Klinikum Rüsselsheimg GmbH</name>
      <address>
        <city>Ruesselsheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Stolberg GmbH</name>
      <address>
        <city>Stolberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hämatologie und Onkologie Stolberg</name>
      <address>
        <city>Stolberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diakonie Krankenhaus Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Troisdorf</name>
      <address>
        <city>Troisdorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Tuebingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Studiengesellschaft Nord-West GmbH</name>
      <address>
        <city>Westerstede</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Athens Medical Centre (IATRIKO)</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Attikon University Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gen. Hos. &quot;Alexandra&quot;</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens G.Gennimatas</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Dunant Hospital Center</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Theageneio Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Attikon</name>
      <address>
        <city>Chaidari</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital &quot;Venizelio&quot;</name>
      <address>
        <city>Heraclion</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Ioannina</name>
      <address>
        <city>Ioannina</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Crete</name>
      <address>
        <city>Iraklio</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital of Agioi Anargyroi</name>
      <address>
        <city>Kifisia</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Larissa</name>
      <address>
        <city>Larissa</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital of Patras &quot;o Agios Andreas&quot;</name>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Metaxa Hospital</name>
      <address>
        <city>Piraeus</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hospital Greece</name>
      <address>
        <city>Piraeus</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Agios Loukas Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Luke Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Greece</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS100070_0110</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Axitinib</keyword>
  <keyword>Renal cell carcinoma</keyword>
  <keyword>Avelumab</keyword>
  <keyword>BAVENCIO®</keyword>
  <keyword>INLYTA®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

